Swiss National Bank Has $103.25 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Swiss National Bank lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.3% in the third quarter, HoldingsChannel reports. The institutional investor owned 375,400 shares of the biopharmaceutical company’s stock after buying an additional 1,000 shares during the period. Swiss National Bank’s holdings in Alnylam Pharmaceuticals were worth $103,246,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of ALNY. Allspring Global Investments Holdings LLC lifted its stake in Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 143 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $26,000. Huntington National Bank lifted its stake in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at about $29,000. Finally, Altitude Crest Partners Inc. acquired a new stake in Alnylam Pharmaceuticals in the 1st quarter valued at about $30,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $232.27 on Tuesday. The company’s 50 day simple moving average is $274.53 and its 200 day simple moving average is $236.10. The stock has a market capitalization of $29.96 billion, a price-to-earnings ratio of -88.65 and a beta of 0.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. During the same quarter in the prior year, the company earned $1.15 EPS. Alnylam Pharmaceuticals’s quarterly revenue was down 33.3% on a year-over-year basis. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ALNY shares. Wolfe Research downgraded shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the company from $198.00 to $370.00 in a report on Friday, August 16th. Bank of America increased their price target on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a report on Monday, October 14th. Finally, Canaccord Genuity Group increased their price target on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.